[{"data":1,"prerenderedAt":185},["ShallowReactive",2],{"drug-alogliptin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":52,"contraindications":75,"warnings":85,"renal":100,"monitoring":110,"interactions":111,"review":112,"examples":115,"atc":121,"iran":123,"usApproval":130,"links":136,"populations":150},"alogliptin",1,{"fa":7,"en":8},"آلوگلیپتین","Alogliptin","alimentary-metabolism",{"fa":11,"en":12},"مهارکننده DPP-4","DPP-4 inhibitor",[14],{"name":15,"market":16},"Nesina","US",[18,19,20,7],"nesina","نزینا","vipidia",[22,36,44],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-25","tablet","oral","25 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},25,"mg",false,[16],[33],{"source":34,"section":35},"fda-nesina","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":41,"refs":42},"tab-12-5","12.5 mg tablet",{"amount":40,"unit":29,"perUnit":24,"scored":30},12.5,[16],[43],{"source":34,"section":35},{"id":45,"form":24,"route":25,"label":46,"concentration":47,"markets":49,"refs":50},"tab-6-25","6.25 mg tablet",{"amount":48,"unit":29,"perUnit":24,"scored":30},6.25,[16],[51],{"source":34,"section":35},[53],{"id":54,"disease":55,"label":56,"population":59,"type":63,"unit":29,"dose":64,"refs":65,"notes":68},"t2dm","type-2-diabetes",{"fa":57,"en":58},"دیابت نوع ۲ بزرگسال — ۲۵ mg یک بار","Type 2 diabetes, adults — 25 mg once daily",{"minAge":60},{"value":61,"unit":62},18,"year","fixed",{"perDose":28,"dosesPerDay":5},[66],{"source":34,"section":67},"2.1",[69],{"text":70,"refs":73},{"fa":71,"en":72},"قرص نصف نشود.","Do not split tablets.",[74],{"source":34,"section":67},[76],{"id":77,"severity":78,"text":79,"refs":82},"hyper","block",{"fa":80,"en":81},"سابقه حساسیت جدی به آلوگلیپتین.","History of serious hypersensitivity to alogliptin.",[83],{"source":34,"section":84},"4",[86,93],{"text":87,"refs":90},{"fa":88,"en":89},"پانکراتیت؛ نارسایی قلب؛ هیپوگلیسمی با انسولین یا سولفونیل‌اوره؛ واکنش حساسیتی؛ درد مفصلی شدید؛ پمفیگوئید بولوز.","Pancreatitis; heart failure; hypoglycaemia with insulin or sulfonylureas; hypersensitivity; severe arthralgia; bullous pemphigoid.",[91],{"source":34,"section":92},"5",{"text":94,"refs":97},{"fa":95,"en":96},"اثرات کبدی (آزمایش کبد پیش از شروع).","Hepatic effects (check liver tests before starting).",[98],{"source":34,"section":99},"5.4",[101],{"egfrBelow":102,"severity":103,"text":104,"refs":107},60,"warn",{"fa":105,"en":106},"ClCr ۳۰ تا \u003C۶۰: ۱۲٫۵ mg؛ زیر ۳۰ و ESRD: ۶٫۲۵ mg یک بار.","CrCl 30–\u003C60: 12.5 mg; \u003C30 and ESRD: 6.25 mg once daily.",[108],{"source":34,"section":109},"2.2",[],[],{"status":113,"reviewer":114,"date":114},"unverified",null,[116],{"regimen":54,"formulation":23,"input":117,"expect":120},{"ageYears":118,"weightKg":119},55,80,{"perDose":28,"tabletsPerDoseRounded":5},[122],"A10BH04",{"status":124,"refs":125},"not-found",[126],{"source":127,"section":128,"url":129},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Alogliptin",{"kind":131,"refs":132,"id":135},"NDA",[133],{"source":34,"section":134},"SPL approval \u002F marketing category","NDA022271",[137,140,144,147],{"kind":138,"url":139,"label":135},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022271",{"kind":141,"url":142,"label":143},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0","FDA Nesina",{"kind":145,"url":146,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa613026.html",{"kind":148,"url":149,"label":122},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BH04",{"pregnancy":151,"lactation":160,"pediatric":168,"geriatric":176},{"level":152,"text":153,"quote":156,"refs":157},"caution",{"fa":154,"en":155},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited data with NESINA in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage.",[158],{"source":34,"section":159},"8.1",{"level":152,"text":161,"quote":164,"refs":165},{"fa":162,"en":163},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of alogliptin in human milk, the effects on the breastfed infant, or the effects on milk production.",[166],{"source":34,"section":167},"8.2",{"level":152,"text":169,"quote":172,"refs":173},{"fa":170,"en":171},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of NESINA have not been established in pediatric patients.",[174],{"source":34,"section":175},"8.4",{"level":177,"text":178,"quote":181,"refs":182},"ok",{"fa":179,"en":180},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between patients 65 years and over and younger patients.",[183],{"source":34,"section":184},"8.5",1792444701172]